Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Acurx Pharmaceuticals Inc. Common Stock
ACXP | US
1.96
USD0.60
44.81%
ACXP | US
Loading StockChartView...
About Acurx Pharmaceuticals Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
1.96
Open
1.38
High
2.04
Low
1.37
Acurx Pharmaceuticals Inc. a clinical stage biopharmaceutical company develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C a potential oral and parenteral treatment targeting gram-positive bacteria including methicillin-resistant staphylococcus aureus vancomycin-resistant enterococcus and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island New York.
View LessACXP | US
Risk
179.3
Sharpe
-0.41
Luna's Score
43/100
Recommendation
Sell
Luna says (ACXP | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
233.9%1 month
179.3%3 months
140.0%6 months
169.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
9.57
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-3.54
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-
MarketCap
31.76M
MarketCap(USD)
31.76M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-346.94
Short ratio
8.41
Short perc.
3.55
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.71
Range1M
0.87
Range3M
3.27
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
17.63
Price X volume
14.77M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.54 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 9.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 140.04 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 31.76M | 3.66B | Emerging |
